GSK - GlaxoSmithKline plc
40.89 0.00 (0.00%)
After hours: 4:37PM EST
| Previous Close | 41.40 |
| Open | 40.89 |
| Bid | 40.70 x 3100 |
| Ask | 41.43 x 1100 |
| Day's Range | 40.73 - 41.21 |
| 52 Week Range | 34.52 - 42.36 |
| Volume | 2,414,749 |
| Avg. Volume | 2,443,393 |
| Market Cap | 97.527B |
| Beta (3Y Monthly) | 0.31 |
| PE Ratio (TTM) | 46.26 |
| EPS (TTM) | 0.88 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 1.96 (4.75%) |
| Ex-Dividend Date | 2018-11-15 |
| 1y Target Est | 44.30 |
- American City Business Journals•15 hours ago
GSK's Triangle nonprofit awards hit $4M after 10 years
After 10 years, GlaxoSmithKline and the Triangle Community Foundation have granted $4 million to local nonprofits as part of their annual Impact Awards.
- Insider Monkey•17 hours ago
Is GlaxoSmithKline (GSK) Right for Your Dividend Portfolio?
“Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- Zacks•2 days ago
Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
- Motley Fool•2 days ago
Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC
Which stock wins in a matchup between these two big drugmakers?
- Zacks•3 days ago
Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
- Business Wire•6 days ago
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.
- Zacks•7 days ago
Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.
Market Realist•7 days agoMylan: Why North America Is a Major Market
In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of GSK.L earnings conference call or presentation 31-Oct-18 2:30pm GMT
Q3 2018 GlaxoSmithKline PLC Earnings Call
- GlobeNewswire•9 days ago
Report: Developing Opportunities within Avon Products, Sanofi, Arch Coal, GlaxoSmithKline plc, Chimera Investment, and PTC — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•9 days ago
Today's Research Reports on Trending Tickers: GlaxoSmithKline and Eli Lilly and Company
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...
Market Realist•9 days agoTeva Pharmaceutical’s Performance in the Third Quarter
In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.
- Zacks•13 days ago
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
- Zacks•14 days ago
Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View
Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.
- American City Business Journals•14 days ago
Big pharma leases almost 500,000 square feet for new research center
It is one of the largest real estate leases in the Bay Area by traditional drug companies staking out space to establish deeper research and development connections with the region’s hundreds of biotech companies and research universities.
Motley Fool•14 days agoGlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript
GSK earnings call for the period ending September 30, 2018.
- Zacks•14 days ago
Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.
- Associated Press•14 days ago
Glaxo: 3Q Earnings Snapshot
On a per-share basis, the Brentford Middlesex, Britain-based company said it had profit of 66 cents. Earnings, adjusted for one-time gains and costs, came to 83 cents per share. The results fell short ...
- Reuters•15 days ago
GSK feels shingles vaccine boost, but shares slip on drugs mix
GlaxoSmithKline's third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focussed on some drugs missing forecasts. GSK beat market a company-compiled analyst forecast with a 14 percent rise in adjusted earnings per share to 35.5 pence, on sales of 8.09 billion pounds ($10 billion), which were up 6 percent on a constant exchange rate basis. Chief Executive Emma Walmsley, who is trying to reinvigorate GSK's pharmaceutical business, its largest division which has lagged rivals in producing new blockbuster drugs, said stronger commercial execution, new launches, notably shingles vaccine Shingrix, and better cost control was driving GSK's growth.
- Reuters•15 days ago
GSK feels shingles vaccine boost, but shares slip on drugs mix
GlaxoSmithKline's third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focussed on some drugs missing forecasts. GSK declared a 19 pence dividend for the quarter, and said it continued to expect 80 pence for the full year.
- The Wall Street Journal•15 days ago
[$$] Glaxo's Shingles Vaccine Gave Earnings a Shot in the Arm
PLC reported a rise in third-quarter earnings and said full-year profit would come in at the top end of expectations, mainly thanks to strong demand for its new shingles vaccine. Demand for Shingrix, which is aimed at people age 50 and over, has outpaced Glaxo’s expectations since it launched the vaccine late last year. The CDC also recommended that adults who had previously received Zostavax should still receive Shingrix.
Reuters•15 days agoGSK feels shingles vaccine boost, but shares slip on drugs mix
GlaxoSmithKline's (GSK.L) third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focussed on some drugs missing forecasts. GSK beat market a company-compiled analyst forecast with a 14 percent rise in adjusted earnings per share to 35.5 pence, on sales of 8.09 billion pounds ($10 billion), which were up 6 percent on a constant exchange rate basis. Chief Executive Emma Walmsley, who is trying to reinvigorate GSK's pharmaceutical business, its largest division which has lagged rivals in producing new blockbuster drugs, said stronger commercial execution, new launches, notably shingles vaccine Shingrix, and better cost control was driving GSK's growth.
- Zacks•15 days ago
Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line
Glaxo beat earnings estimates while sales were in-line in the third quarter of 2018.
- The Wall Street Journal•15 days ago
[$$] GlaxoSmithKline 3Q Profit Rose, Raises Guidance
PLC (GSK.LN) said Wednesday that third-quarter net profit rose 17% and revised its full-year outlook toward the upper end of its forecasted range on the back of a strong performance of its shingles vaccine. Adjusted operating profit, a measure which strips out one-time items, was GBP2.52 billion--a 6% increase at constant exchange rates when compared with the third quarter of 2017. The FTSE 100-listed drugmaker narrowed its outlook, and said it sees adjusted earnings per share increasing between 8% to 10% at constant exchange rates for the full-year regardless of whether a generic Advair competitor is launched.
